AR113906A1 - Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple - Google Patents
Régimen con cladribina para tratar formas progresivas de la esclerosis múltipleInfo
- Publication number
- AR113906A1 AR113906A1 ARP180103432A ARP180103432A AR113906A1 AR 113906 A1 AR113906 A1 AR 113906A1 AR P180103432 A ARP180103432 A AR P180103432A AR P180103432 A ARP180103432 A AR P180103432A AR 113906 A1 AR113906 A1 AR 113906A1
- Authority
- AR
- Argentina
- Prior art keywords
- cladribine
- multiple sclerosis
- regime
- progressive forms
- treat progressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Cladribina para usar en el tratamiento oral de pacientes que padecen formas progresivas de esclerosis múltiple, caracterizada porque dicha cladribina se ha de administrar en forma oral a cada paciente a una dosis fija por paciente, por peso corporal y por año de tratamiento, donde dicha dosis fija se selecciona del rango de 1,5 mg/kg a 4,0 mg/kg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762590442P | 2017-11-24 | 2017-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113906A1 true AR113906A1 (es) | 2020-06-24 |
Family
ID=64457023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103432A AR113906A1 (es) | 2017-11-24 | 2018-11-23 | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple |
Country Status (15)
Country | Link |
---|---|
US (3) | US10849919B2 (es) |
EP (1) | EP3713582A1 (es) |
JP (1) | JP7495345B2 (es) |
KR (1) | KR20200090824A (es) |
CN (1) | CN111356460A (es) |
AR (1) | AR113906A1 (es) |
AU (1) | AU2018372007A1 (es) |
BR (1) | BR112020010282A2 (es) |
CA (1) | CA3083328A1 (es) |
EA (1) | EA202091253A1 (es) |
IL (1) | IL274777A (es) |
MX (2) | MX2020005266A (es) |
SG (1) | SG11202004772RA (es) |
TW (1) | TW201936199A (es) |
WO (1) | WO2019101960A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021342333A1 (en) * | 2020-09-10 | 2023-04-06 | Merck Patent Gmbh | Novel treatment regimen for the treatment of autoimmune disorders |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
PT801571E (pt) | 1994-12-22 | 2002-12-31 | Ortho Pharma Corp | Formulacoes soluveis de 2-cloro-2'-desoxiadenosina |
US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
JP4757632B2 (ja) | 2002-09-25 | 2011-08-24 | ブリガム ヤング ユニバーシティー | 2’−デオキシグアノシンから2−クロロ−2’−デオキシアデノシンを調製する方法 |
RS20050735A (en) | 2003-03-28 | 2008-06-05 | Ares Trading S.A., | Cladribine formulations for improved oral and transmucosal delivery |
EA009714B1 (ru) | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки |
PL2805723T3 (pl) * | 2004-12-22 | 2018-04-30 | Merck Serono Sa | Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego |
JP2009537605A (ja) * | 2006-05-24 | 2009-10-29 | メルク セローノ ソシエテ アノニム | 多発性硬化症を治療するためのクラドリビン・レジメン |
US10000516B2 (en) * | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
-
2018
- 2018-11-23 AR ARP180103432A patent/AR113906A1/es unknown
- 2018-11-23 JP JP2020528327A patent/JP7495345B2/ja active Active
- 2018-11-23 MX MX2020005266A patent/MX2020005266A/es unknown
- 2018-11-23 CN CN201880075672.5A patent/CN111356460A/zh active Pending
- 2018-11-23 AU AU2018372007A patent/AU2018372007A1/en active Pending
- 2018-11-23 CA CA3083328A patent/CA3083328A1/en active Pending
- 2018-11-23 SG SG11202004772RA patent/SG11202004772RA/en unknown
- 2018-11-23 EA EA202091253A patent/EA202091253A1/ru unknown
- 2018-11-23 KR KR1020207017364A patent/KR20200090824A/ko not_active Application Discontinuation
- 2018-11-23 TW TW107141805A patent/TW201936199A/zh unknown
- 2018-11-23 EP EP18808004.8A patent/EP3713582A1/en active Pending
- 2018-11-23 WO PCT/EP2018/082434 patent/WO2019101960A1/en unknown
- 2018-11-23 US US16/199,119 patent/US10849919B2/en active Active
- 2018-11-23 BR BR112020010282-2A patent/BR112020010282A2/pt unknown
-
2020
- 2020-05-19 IL IL274777A patent/IL274777A/en unknown
- 2020-07-13 MX MX2023007405A patent/MX2023007405A/es unknown
- 2020-10-23 US US16/949,278 patent/US20210169912A1/en active Pending
-
2022
- 2022-09-16 US US17/932,796 patent/US20230021880A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021504363A (ja) | 2021-02-15 |
US10849919B2 (en) | 2020-12-01 |
KR20200090824A (ko) | 2020-07-29 |
EA202091253A1 (ru) | 2020-09-29 |
CN111356460A (zh) | 2020-06-30 |
SG11202004772RA (en) | 2020-06-29 |
TW201936199A (zh) | 2019-09-16 |
IL274777A (en) | 2020-07-30 |
AU2018372007A1 (en) | 2020-07-09 |
MX2020005266A (es) | 2020-09-18 |
CA3083328A1 (en) | 2019-05-31 |
JP7495345B2 (ja) | 2024-06-04 |
US20190167707A1 (en) | 2019-06-06 |
BR112020010282A2 (pt) | 2020-11-17 |
US20230021880A1 (en) | 2023-01-26 |
US20210169912A1 (en) | 2021-06-10 |
EP3713582A1 (en) | 2020-09-30 |
WO2019101960A1 (en) | 2019-05-31 |
MX2023007405A (es) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MX2021002321A (es) | Nuevos metodos. | |
JP2017506624A5 (es) | ||
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
MX2021002322A (es) | Nuevos metodos. | |
AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
AR100784A1 (es) | Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador | |
CL2021001389A1 (es) | Formulaciones en cápsula | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
AR113906A1 (es) | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple | |
CO2019003808A2 (es) | Composición farmacéutica que comprende antagonista receptor de mineralocorticoides y uso de la misma | |
AR102308A1 (es) | Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico | |
MX2018015208A (es) | Andrografolido para tratar formas progresivas de esclerosis multiple. | |
UY32670A (es) | Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica | |
CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
AR112229A1 (es) | Composición farmacéutica para usar en el tratamiento o la prevención de deficiencias de vitaminas y deficiencias de minerales en pacientes que fueron sometidos a una cirugía de banda gástrica | |
HRP20211309T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti | |
BR112018009476A8 (pt) | regime de dosagem de plasminogênio para cicatrização de ferimentos | |
MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. |